Link between Cancer and Hormone replacement therapy – Pubrica

1. LINK BETWEEN CANCER AND HORMONE REPLACEMENTTHERAPY An Academic presentationby Dr. Nancy Agens, Head, Technical Operations, Pubrica Group: www.pubrica.com Email:sales@pubrica.com

2. Today'sDiscussion Outline ofTopics Inbrief Introduction Menopausal Hormone Therapy (MHT) What ResearchSays Does Hormone Replacement Therapy (HRT) IncreaseRisk Conclusion FutureScopes

3. InBrief Usage of Hormonal Replacement Therapy has its advantages and disadvantages. Women should be careful in selecting hormone treatments. It is better to review the treatment intake every once in six months to understand itsmechanism.

4. Menopausal Hormone Therapy has mainly used inWestern countries since1970. Women tend to start MHT at around menopause and may continue for severalyears. Introduction Breast cancer at these ages is the most common malignancy in Western countries and diagnosed in about 3% of women in their50s. Most individual works were too limited to accurately analyse the long-term risk of breast cancer associated with the use of MHT in just a fewyears.

5. Menopausal Hormone Therapy(MHT) Menopausal hormone therapy (MHT) affords fantastic relief from climacteric symptoms, but some are associated with increased risk of stroke, venous thromboembolism, and cancers of the breast, ovary andendometrial. The Women’s Health Initiative trial and the Million Women Study has highlighted the effects of prescribing Hormone therapy and its association on the risk of breastcancer. However, there are limitations in the way data were obtained and analysed in most epidemiological studiespublished. This articlewill highlight the actual relationship between cancer and hormonetherapy.

6. What ResearchSays Hormones can kill cancer cells in different cases, cause cancer cells to grow extra slowly, or abandon them fromgrowing. Systemichormone treatment users who began around the time of menopause have been at higher risk of invasive breast cancer than users who never apparentlyconsume. The risk used to be higher for estrogen-progestagen than for estrogen-only preparations, especially if they use progestagen as a substitute once a day rather than an intermittent one.

7. Does Hormone Replacement Therapy (HRT) IncreaseRisk The risk of breast cancer will increase for postmenopausal women taking some type ofHRT. But for those who use combined HRT, which has estrogen and progestogen hormones, this is themaximum. Womb cancer threat differs depending on the type ofHRT. Oestrogen-only HRT increases the risk of cancerfrom thewomb. Oestrogen-only HRT is typically given exclusively to those who have removed two of their wombs because they have no womb to continue with cancerhazard.

8. Conclusion One difficulty of all the handy epidemiological evidence is that after cessation of extended use of MHT by women who started some years of hormonal therapy at around the time of menopause, there is still not long enoughfollow-up. Another problem is that the collaboration sought statistics only on the incidence of breast cancer, not mortality now, and the incidence may depend on the sensitivity and frequency of mammographicscreening.

9. FutureScopes The attitude towards the usage of Hormonal replacement therapy should beencouraged. The usage of HRT can be used for the momentary remedy of menopausal signs. Women thinking about the use of HRT need to be informed of its risks and benefits. Hormonal therapy should not be used for the prevention of anydisease.

10. ContactUs UNITEDKINGDOM +44-1143520021 INDIA +91-9884350006 EMAIL sales@pubrica.com